• Morgan Stanley sets a price target of $92 for Incyte Corporation (NASDAQ:INCY), indicating a potential decline in stock value.
• First Trust Advisors LP reduces its holdings in Incyte, aligning with Morgan Stanley's cautious outlook.
• Investor actions vary, with some increasing their stakes, reflecting differing perspectives on Incyte's potential.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics. On December 8, 2025, Morgan Stanley set a price target of $92 for INCY. At that time, the stock was priced at $96.47, showing a -4.63% difference from the target. This suggests that Morgan Stanley anticipates a potential decline in the stock's value.

First Trust Advisors LP has reduced its holdings in Incyte by 1.6% during the second quarter, selling 12,101 shares. This leaves them with 761,227 shares, representing about 0.39% of the company, valued at $51.8 million. This move aligns with the price target set by Morgan Stanley, indicating a cautious approach towards the stock.

Other investors have shown varied interest in Incyte. Cetera Investment Advisers increased its stake by 10.2% in the first quarter, now holding 14,644 shares valued at $887,000. Similarly, Vanguard Group Inc. expanded its stake by 2.1%, now owning 19,997,823 shares. These actions reflect differing investor perspectives on the company's potential.

The stock for INCY is currently priced at $96.29, marking a 6.08% decrease with a $6.24 drop. Today, the stock fluctuated between $96 and $100.43. Over the past year, it reached a high of $109.28 and a low of $53.56. The company's market capitalization stands at approximately $18.9 billion, with a trading volume of 814,496 shares.